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ABSTRACT
Background: Theophylline is a useful drug for the treatment of asthma. The Asthma Prevention and Manage-
ment Guidelines (JGL) recommend use of sustained-release theophylline products as controllers and of in-
jectable aminophylline products as relievers. The Global Initiative for Asthma: Global Strategy for Asthma Man-
agement and Prevention, the NHLBWHP Workshop Report 1995 (GINA, 1995) and guidelines in Western
countries recommend sustained-release theophylline, but not as positively as in the JGL. The aim of this survey
was to determine the occurrence of serious adverse reactions.
Methods: The survey was conducted in 66 institutions staffed by physicians certified by the Japanese Society
of Allergology (JSA). The target diseases were asthma and COPD including chronic bronchitis and pulmonary
emphysema, which are indications for use of sustained-release theophylline products in Japan.
Results: 3,921 patients were included in the safety evaluation. No serious adverse reactions were observed
among the patients in this survey, although 54 patients (1.38%) exhibited non-serious adverse reactions. The
incidence of adverse reactions was found to be high in patients who had begun use of sustained-release theo-
phylline products at the time of registration in this survey, and in patients who were concomitantly taking
macrolide antibiotics.
Conclusions: The present survey demonstrates that sustained-release theophylline is safe, as long as used
appropriately, although adverse reactions tend to develop early after initiation of administration.
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INTRODUCTION
Theophylline has long been used as a bronchodilator.
Sustained-release theophylline products have been
used for continuous suppression of asthmatic symp-
toms such as wheezing and dyspnea because of the
long duration of their efficacy . Recently , the anti-
inflammatory effects of theophylline such as suppres-
sion of infiltration of T-cells and eosinophils into the
airway, inhibition of proliferation of T-cells, produc-
tion of cytokines , and induction of apoptosis of
eosinophils and neutrophils have been reported . 1-6
Enhancement of histone deacetylase (HDAC) activity
has also been reported.7 Such anti-inflammatory ef-
fects have become the focus of interest as a new as-
pect of theophylline efficacy.
The bronchodilator activity of theophylline is dose-
dependent,8 and its therapeutic range is set at 5 to 20
mcgmL. Anti-inflammatory effects are observed at 5
mcgmL and above . The Asthma Prevention and
Management Guidelines9 developed in Japan set the
target blood theophylline concentration at 5 to 15
mcgmL and recommended that sustained-release
theophylline products be used as controllers in per-
sistent asthma of mild to severe severity.
In contrast, the Global Initiative for Asthma: Global
Strategy for Asthma Management and Prevention ,
the NHLBWHP Workshop Report 1995 (GINA ,
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Table 1 ICH definition of seriousness of adverse reac-
tions＊ 13
Serious:
1. Results in death or injury
2. Is life-threatening or may result in injury
3. Requires hospitalization or prolongation of existing hos-
pitalization
4. Results in congenital disease or abnormality in the next 
generation
5. Other events that may require intervention to prevent 
one of the outcomes listed in the definition 1―4.
Moderate: Neither severe nor mild
Mild: When symptoms are judged to be mild by the 
physician-in-charge and easily recoverable.
(＊ ICH: International Conference of Harmonization of Tech-
nical Requirements for Registration of Pharmaceuticals for Hu-
man Use)
1995), which was prepared as an international guide-
line in 1995, 10 recommends the use of sustained-
release theophylline products and injectable methylx-
anthine products, but theophylline products are not
recommended as first-line medication because of
fears about the possible occurrence of serious ad-
verse reactions.
Sustained-release theophylline products have also
been used in the treatment of COPD including em-
physema and chronic bronchitis . Sustained-release
theophylline products are designated as supplemen-
tal drugs in the Japanese COPD guidelines.11 These
guidelines state that these drugs should be used only
when inhalational therapy with anti-cholinergic drugs
and β2-agonists is insufficient. The Global Initiative
for Chronic Obstructive Lung Disease12 states that in-
halation bronchodilators are preferable to sustained-
release theophylline products in terms of possible ad-
verse reactions, despite an acknowledgment of the ef-
fectiveness of sustained-release theophylline prod-
ucts.
We believe, however, that the safety of sustained-
release theophylline has been demonstrated based
on the actual widespread use of sustained-release the-
ophylline products in Japanese adult patients. How-
ever, no survey supporting the safety of these prod-
ucts has been conducted. Thus, we conducted a pro-
spective survey to determine the occurrence of seri-
ous adverse reactions induced by or related to
sustained-release theophylline products, in adult pa-
tients ranging from 15 to 64 years of age with asthma
or COPD in Japan at institutions staffed with physi-
cians certified by the Japanese Society of Allergology
(JSA). The aim of this survey was to finally confirm
the safety of sustained-release theophylline products.
METHODS
SURVEY METHODS
The survey was conducted in 66 institutions staffed
by physicians certified by the JSA. The target dis-
eases were asthma and COPD including chronic
bronchitis and pulmonary emphysema, which are in-
dications for use of sustained-release theophylline
products in Japan. The subjects ranged in age from
15 to 64 years. The period of patient registration was
1 month set separately and in advance by each par-
ticipating institution between September 1 and De-
cember 31 in 2001. The observation period was 1
month after the registration of each patient, and ad-
verse reactions observed during the observation pe-
riod were recorded.
SURVEY ITEMS
The following items were surveyed: sex, age, date of
registration, diseases (reason for use), dose and term
administration , concomitant drugs ( therapy and
medication), adverse reactions and blood theophyl-
line concentration (if present, type of the adverse re-
action , seriousness and date of occurrence ) , and
course and treatment for adverse events, vital signs,
results of general and biochemical hematological ex-
aminations and urine examinations performed before,
during and after the administration of theophylline
(required in cases of a serious adverse reaction). Ad-
verse events were reviewed by the physician at the
visit to the clinic. The seriousness of adverse reac-
tions was evaluated according to the following criteria
in accordance with the International Conference of
Harmonization of Technical Requirements for Regis-
tration of Pharmaceuticals for Human Use (ICH) cri-
teria ( Table 1 ).13
RESULTS
BREAKDOWN OF PATIENTS
The 66 institutions where the survey was conducted
are shown in Table 2. A total of 4,983 patients from
these institutions participated in this survey out of
which 1,062 patients were excluded. Specifically, 739
patients fell out of the designated age range (under
15 years and over 65 years), 177 were not observed
for the total observation period (25 days or less), 55
violated the registration protocol such as being regis-
tered outside the registration period, 49 were regis-
tered twice, 33 did not suffer from the targeted dis-
ease and 9 failed to come back to the hospital. Ulti-
mately 3,921 patients were included in the safety
evaluation.
PATIENT BACKGROUND FACTORS
The background factors of patients who were the tar-
get of safety evaluation and occurrence of adverse re-
actions are shown in Table 3. There were 1,967 males
(50.2%) and 1,954 females (49.8%). The largest num-
ber of patients were in their 50s at 1,190 (30.3%), and
patients who were 40 years of age or older numbered
2,710 ( 69.1% ) . The disease ( reason for use ) was
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Table 2 Institutions that participated in the survey (in alphabetical order)
Nihon University Itabashi HospitalAichi Medical University
Nigata UniversityAsahi Chuo Hospital
Ogaki Municipal HospitalChiba University
Okayama Red Cross General HospitalChukyo Hospital
Okayama UniversityDoai Memorial Hospital
Osaka City University Medical SchoolDokkyo University School of Medicine
Rosai Hospital for SilicosisEhime Prefectural Central Hospital
Saitama Medical SchoolFujita Health University School of Medicine
Sendai National Hospital Fukushima Medical University
Sendai Open HospitalGunma University School of Medicine
Shimonita Kosei HospitalHanzomon Hospital
Shizuoka Red Cross HospitalHitachi Totsuka General Hospital
Showa General HospitalInternational Medical Center of Japan
Showa University Fujigaoka HospitalIshikawa Prefectural Central Hospital
Showa University School of Medicine Iwate Medical University
Teikyo University School of MedicineJapanese Red Cross Medical Center
Toho University School of MedicineJobu Hospital for Respiratory Disease
Toho University School of Medicine, Sakura HospitalKameda General Hospital
Tohoku Rosai HospitalKariya General Hospital
Tohoku University School of MedicineKihara Hospital
Tokyo Kyosai HospitalKinki University School of Medicine
Tokyo Medical and Dental UniversityKurume University
Tokyo Metropolitan Hiroo General HospitalMaebashi-Kita Hospital
Tone Chuo HospitalMazda Hospital
Tosei General HospitalMeitetsu Hospital
Toyoko Hospital, St. Marianna University School of MedicineNagoya Ekisaikai Hospital
Toyota Memorial HospitalNagoya University
University of TokyoNara Hospital Kinki University School of Medicine
Yokohama City Seibu Hospital, St. Marianna University School of MedicineNational Fukuoka-Higashi Hospital
Yokohama City University School of MedicineNational Minami-Fukuoka Chest Hospital
Yugawara Kosei-Nenkin HospitalNational Numata Hospital
Yukawa Naika ClinicNational Okayama Medical Center
National Sagamihara Hospital
National Sanatorium Minami Okayama Hospital
asthma in 3,659 patients (93.3%), COPD in 203 pa-
tients (5.2%) , and asthma + COPD in 59 patients
(1.5%) .
At the time of registration, 2,856 patients (72.8%)
had been receiving sustained-release theophylline
products for 1 year or more. The dose of sustained-
release theophylline products was 400 mgday or
less in 3,398 patients (86.7%), and between 301 and
400 mgday in 2,413 (61.5%) of these. The mean
dose ( ± S.D.) was 382.4 ± 132.4 mgday (100 to
1,600 mgday)(not shown in the table).
Among the patients included in the safety evalu-
ation , blood theophylline concentration was meas-
ured in 81 patients who were treated with sustained-
release theophylline continuously, and the observed
round-the-clock (RTC) concentrations were 1.83 to
19.79 mcgmL(mean ± S.D.: 8.84 ± 3.47 mcgmL).
Only 3 patients with blood concentrations of 15.93,
17.3 and 19.97 mcgmL had concentrations higher
than the target blood concentration recommended by
the Asthma Prevention and Management Guidelines
(JGL), but none exceeded the possible toxic concen-
tration of 20 mcgmL.
A total of 3,679 patients took other drugs concomi-
tantly, mainly corticosteroids (3,156 cases, 85.8%) and
β-agonists (2,256 cases, 61.3%).
OCCURRENCE OF ADVERSE REACTIONS
No serious adverse reactions were observed among
the 3,921 patients included in the safety evaluation.
Seventy-one non-serious adverse reactions were ob-
served in 54 patients ( adverse reaction incidence
rate: 1.38%). The main non-serious adverse reactions
were nervous system disorders (14 incidents: 0.36%)
such as tremor and hypertonia, gastrointestinal disor-
ders (14 incidents: 0.36%) such as nausea and dyspep-
Allergology International Vol 55, No4, 2006 www.jsaweb.jp 397
Safety of Sustained-Release Theophylline
Table 3 Background factors of patients included in the safety evaluation and occurence of adverse reactions
P 
(χ2 test)
Adverse drug 
reaction
(%)
No. of 
patients
Factor
P
(χ2 test)
Adverse drug 
reaction
(%)
No. of 
patients 
Factor
(%)
No. of 
patients
(%)
No. of 
patients
Concomitant drugs(1.38)543,921Total number of patients 
N.S.(0.83)2(6.2)242　NoneGender
(1.41)52(93.8)3,679　AnyN.S.(1.47)29(50.2)1,967　Male
―(1.46)33(61.3)2,256β2-agonist(1.28)25(49.8)1,954　Female
(1.98)26(35.6)1,310　InhaledAge (years)
(0.62)6(26.3)969　OralN.S.(0.00)0(2.1)83　15＜＿  ＜20
(0.57)3(14.2)522　Patch(0.89)4(11.5)449　20＜＿  ＜30
―(1.49)47(85.8)3,156Corticosteroid(1.33)9(17.3)679　30＜＿  ＜40
(1.55)47(82.2)3,023　Inhaled(1.97)14(18.1)710　40＜＿  ＜50
(0.40)2(13.6)500　Oral(1.43)17(30.3)1,190　50＜＿  ＜60
―(0.82)15(49.5)1,822Anti-alergic drugs1)(1.23)10(20.7)810　60＜＿  ＜65
―(4.02)10(6.8)249Anti-microbial agentDiseases
(4.85)10(5.6)206　MacrolideN.S.(1.37)50(93.3)3,659　Asthma
(0.00)0(0.4)14　New quinolone(1.48)3(5.2)203　COPD
(5.56)1(0.5)18　Others(1.69)1(1.5)59　Asthma ＋ COPD
―(5.88)3(1.4)51Other methylxan-
thine products
Period of administration before registration
＊＊＊(7.45)7(2.4)94　No administration
(0.00)0(0.7)24　Oral2)(1.76)4(5.8)227　＜1 month
(12.5)3(0.7)24　Injected(0.92)4(11.1)437　1 month＜＿  ＜6 months
(0.00)0(0.00)0　Suppository(1.30)4(7.8)307　6 months＜＿  ＜1 year
(0.00)0(0.08)3　Not described(1.23)35(72.8)2,856　1 year＜＿ 
Dose of theophyline (mg/day)
N.S.(1.88)16(21.8) 853　＜＿ 200
(1.52)2(3.4)132　201＜ ＜＿300
(1.37)33(61.5)2,413　301＜ ＜＿400
(0.57)3(13.3)523　400＜
N.S.: not significant ＊＊＊: P＜0.001
Note) The percentages of concomitant drugs by type are the percentages of total number of patients who used concomitant drugs  
(3,679 patients).
1) Anti-alergic drugs: DSCG, leukotriene modifiers, second-generation antihistamines (H1-antagonists) and other oral antialergic compounds
2) Other methylxanthine products (oral): short acting methylxanthine products (aminophyline, choline theophyline, diprophyline)
sia , and abnormal laboratory test results ( 29 inci-
dents: 0.74%) such as hyperuricemia ( Table 4 ).
Among the patients who exhibited adverse reac-
tions, an RTC blood theophylline concentration was
present in 29 patients, and the concentration ranged
from 2.9 to 17.3 mcgmL (mean ± S.D.: 8.76 ± 3.48
mcgmL ) ; only 1 patient exhibited a concentration
higher than the target blood concentration recom-
mended by the JGL of 15 mcgmL.
OCCURRENCE OF ADVERSE REACTIONS
BY PATIENT BACKGROUND FACTORS
The occurrence of adverse reactions observed in the
3,921 patients included in the safety evaluation are
shown in Table 3.
The incidence of adverse reactions in patients who
started receiving sustained-release theophylline prod-
ucts at the time of registration was 7.45% and signifi-
cantly higher than that in patients who had been re-
ceiving sustained-release theophylline products be-
fore registration ( p < 0.001).
The incidence of adverse reactions among patients
taking concomitant drugs was high in patients receiv-
ing macrolide antibiotics (4.85%) and patients receiv-
ing injectable methylxanthine products ( 12.5% ) .
Among the patients who started receiving administra-
tion at the time of registration, 12 adverse reactions
were observed in 7 patients (Table 5) with 4 cases of
nausea and 2 each of palpitations and tremor. The
number of days to the time of onset of adverse reac-
tions was within 5 days after the start of administra-
tion in 5 of 7 patients.
Twelve adverse reactions were observed in 10 of
the 206 patients receiving concomitant macrolide an-
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Table 4 List of adverse reactions
Number of patients exhibiting adverse reactions: 54
29 incidentsAbnormal laboratory tests
Hyperuricemia (16), blood uric acid increased (4), blood 
creatine phosphokinase increased (6), aspartate amino-
transferase increased (2) and alanine aminotransferase 
increased (1)
14 incidents Nervous system disorders
Tremor (6), hypertonia (2), dizziness (2), insomnia (2), hy-
poaesthesia (1) and headache (1)
14 incidents Gastrointestinal disorders
Nausea (6), indigestion (3), bloating (3), vomiting (1) and 
diarhea (1)
 9 incidents Cardiovascular disorders
Palpitations (9)
 2 incidents Metabolic and nutritional disorders
Appetite decreased (1) and anorexia (1)
 2 incidentsSkin and subcutaneous tissue disorders
Pruritus (2)
 1 incidentGeneral disorders
Malaise (1)
tibiotics (Table 6) with 2 cases of nausea, 1 each of
tremor, dyspepsia and palpitations, and 7 of abnormal
laboratory test results such as hyperuricemia.
DISCUSSION
No serious adverse reactions were observed among
the 3,921 patients included in the safety evaluation in
this survey. A possible reason for the absence of seri-
ous adverse reactions is that this survey was con-
ducted in institutions with physicians who were ex-
perts in the treatment of asthma and COPD and certi-
fied as specialists by the JSA. Furthermore, the stan-
dard dose for use as a controller is 400 mgday and
the target blood concentration is 5 to 15 mcgmL ac-
cording to the JGL. A total of 3,398 patients (86.7%)
received doses of 400 mgday or less . The mean
blood concentration in 81 patients who underwent
RTC measurement of blood theophylline concentra-
tion was 8.84 ± 3.47 mcgmL(1.83 to 19.79 mcgmL).
Only 3 patients exhibited concentrations higher than
15 mcgmL , and none exhibited concentrations
higher than 20 mcgmL, the potentially toxic level.
Treatment with sustained-release theophylline can
be considered safe as long as treatment is conducted
in accordance with the JGL guidelines of a target
blood concentration level of 5 to 15 mcgmL. Even if
the clearance rate is adversely affected for any rea-
son, it is still highly unlikely that the blood theophyl-
line concentration would hit the potentially toxic level
of 20 mcgmL.
Non-serious adverse reactions were found in 1.38%
of cases, and the main reactions were nervous system
disorders such as tremor and hypertonia, gastrointes-
tinal disorders such as nausea and dyspepsia, and ab-
normal laboratory test results such as hyperuricemia.
Of 54 adverse reactions, an RTC blood theophylline
concentration was present in 29. Concentrations
ranged from 2.9 to 17.3 mcgmL, and only 1 patient
exhibited a concentration higher than 15 mcgmL
and also exhibited mild hyperuricemia. In several of
clinical trials of preparations of sustained-release the-
ophylline in Japan, a total of 517 subjects received the
preparations. 14-16 No serious side effects were re-
ported, and 10.06% (52517) of the subjects showed
non-serious side effects. The reason of higher inci-
dences of non-serious side effects in other clinical tri-
als is not clear, since the survey methods were differ-
ent from those used in the present study. Another
possibility is that around 70% of subjects in this sur-
vey had been on sustained-release theophylline at the
start of the survey and might have developed toler-
ance to these preparations before the survey. Wein-
berger reported complaints during chronic therapy in
1―2%17,18 of patients, which is similar to the percent-
age in the present survey. It should be noted that this
study was intended to study the occurrence of “seri-
ous side effects” and not that of “non-serious side ef-
fects”.
Patients who started receiving sustained-release
theophylline at the time of registration exhibited a
significantly higher incidence of adverse reactions ,
namely 7 of 94 patients. The adverse reactions ob-
served were already known and 5 of 7 continued
medication (Table 5). Safe administration is possible
with attention paid to development of adverse reac-
tions in the early period of treatment.
Seventy three percent of the patients had received
sustained-release theophylline and patients who
showed serious side effects might have been ex-
cluded for the use of sustained-release preparations.
However, the above-mentioned clinical trials in Japan
and double-blind clinical trials in the United states
Europe did not report serious side effects when pa-
tients were given sustained-release theophyllines. In
these trials no sustained-release theophylline was
given before the trials.19-25
The incidence of adverse reactions in patients con-
comitantly receiving macrolide antibiotics was 4.85%
(10206 patients) which is higher than that observed
in patients receiving other concomitant drugs .
Macrolide antibiotics inhibit CYP1A2 and may in-
crease blood theophylline concentration.26 However,
none of 10 patients in the current survey who con-
comitantly received macrolide antibiotics and experi-
enced an adverse reaction, exhibited a blood theo-
phylline concentration of over 20 mcgmL, which
may cause an adverse reaction.8 Only the 1 patient
who had a blood theophylline concentration of 17.3
mcgmL actually had a target blood concentration
higher than that recommended by the JGL. Admini-
stration of sustained-release theophylline was not dis-
continued in any of the 10 patients with adverse reac-
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Table 5 Outline of occurence of adverse reactions (patients who began receiving theophyline administration at the time of 
registration)
Theophyline
concentration in 
RTC
Name of adverse reaction
(severity)
Time of occurence of adverse
reaction (treatment)
Concomitant drugs
Dose of
theophyline
Sex, age (years)
Reason for use
11.2 mcg/mLNausea (mild)
Day 1 of administration
(continued)
β2 (inhaled), CS 
(inhaled, oral)
400 mg/day1. Female, 26
Asthma
Not measuredNausea, dizziness (dizziness on 
standing up, giddiness), 
palpitations, tremor (moderate)
Day 1 of administration
(discontinued)
β2 (inhaled), CS 
(inhaled)
400 mg/day2. Female, 21
Asthma
13.8 mcg/mLTremor, nausea (moderate)
Day 2 of administration (dose-
decreased)
β2 (inhaled), CS 
(inhaled, injected), 
Mc, Am (injected)
400 mg/day3. Female, 53
Asthma
Not measuredPalpitations (mild)
Day 4 of administration (dose-
decreased)
β2 (inhaled), CS 
(inhaled)
400 mg/day4. Female, 31
Asthma
Not measuredNausea (moderate)
Day 5 of administration (dose-
decreased)
β2 (inhaled), CS 
(inhaled), Mc, 
Am (injected)
400 mg/day5. Female, 44
Asthma
Not measuredHeadache (slight)
Day 15 of administration
(discontinued)
CS (inhaled)400 mg/day6. Female, 27
Asthma
 6.9 mcg/mLHyperuricemia (mild)
Day 29 of administration
(continued)
Mc200 mg/day7. Male, 62
COPD
β2: β2-agonist CS: corticosteroid Mc: macrolide Am: aminophyline
Table 6 Outline of occurence of adverse reactions (patients concomitantly receiving macrolide antibiotics)
Theophyline
concentration in
RTC
Treatment
Name of adverse
reaction
(severity)
Concomitant
drugs other
than macrolide
Dose of theophyline
Period of administration
before registration
Sex, age (years)
Reason for use
13.8 mcg/mLDose-decreasedTremor, (moderate)
Nausea (moderate)
β2 (inhaled),
CS (inhaled), 
Am (injected)
400 mg/day
Administration started at 
the time of registration
1. Female, 53
Asthma
Not measuredDose-decreasedNausea (moderate)β2 (inhaled), 
CS (inhaled), 
Am (injected)
400 mg/day
Administration started at 
the time of registration
2. Female, 44
Asthma
 8.6 mcg/mLContinuedDyspepsia (mild)
(possibly due to cephem)
β2 (inhaled), 
CS (inhaled), 
Aa, cephem
400 mg/day
Less than 1 month
3. Male, 30
Asthma
 9.2 mcg/mLContinuedPalpitation (mild)β2 (oral)
CS (inhaled), 
Aa
400 mg/day
1 year or more
4. Male, 58
Asthma
 6.9 mcg/mLContinuedHyperuricemia (mild)None200 mg/day
Administration started at 
the time of registration
5. Male, 62
COPD
17.3 mcg/mLContinuedHyperuricemia (mild)CS (inhaled)200 mg/day
1 month―half a year
6. Male, 61
COPD
 8.6 mcg/mLContinuedHyperuricemia (mild)
AST (GOT)
increased (mild)
CS (inhaled)200 mg/day
Half a year―1 year
7. Male, 62
COPD
tions. This problem could probably be avoided by ad-
justing the dosage to bring the blood concentration
level within the standard set by the JGL.
The incidence of non-serious adverse reactions
among the 733 patients not included in the safety
evaluation because they were over 65 years of age
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was 0.8% (6733). The mean dose was 348.3 mgday
for these patients, which is lower than among the pa-
tients included in the evaluation (382.4 mgday) .
This difference in dosage can probably be attributed
to adjustments in dosage which took into considera-
tion lowered metabolism found among the elderly.
As the aim of this survey was to confirm the safety
of sustained-release theophylline products, we did not
survey the effectiveness of these products. However,
we assumed that effective dosages had been adminis-
tered in regular treatments according to the JGL
guidelines in the surveyed cases. Accordingly, we be-
lieve that there were no particular problems regard-
ing the effectiveness of these products in this survey.
Finally, the price of sustained-release theophylline
products is lower than that of other therapeutic drugs
for asthma. Therefore, the most recent issue of GINA
2002 27 recommended the wide use of sustained-
release theophylline products from the standpoint of
medical economy.
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